ULTRAGENYX PHARMACEUTICAL INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 124.54K shares, a 40.64% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 209.79K shares, a 60.31% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 130.87K shares, a 80.97% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares 10-K · filed 2026-02-18 | |
| 2024-12-31 | 124.54K shares 10-K · filed 2025-02-19 | |
| 2023-12-31 | 209.79K shares 10-K · filed 2024-02-21 | |
| 2022-12-31 | 130.87K shares 10-K · filed 2023-02-17 | |
| 2021-12-31 | 687.84K shares 10-K · filed 2022-02-15 | |
| 2020-12-31 | 1.51M shares 10-K · filed 2022-02-15 | |
| 2019-12-31 | 235.68K shares 10-K · filed 2022-02-15 | |
| 2018-12-31 | 713.26K shares 10-K · filed 2021-02-12 | |
| 2017-12-31 | 478.47K shares 10-K · filed 2020-02-14 | |
| 2016-12-31 | 425.92K shares 10-K · filed 2019-02-20 | |
| 2015-12-31 | 795.83K shares 10-K · filed 2018-02-21 | |
| 2014-12-31 | 305.09K shares 10-K · filed 2017-02-17 | |
| 2013-12-31 | 307.37K shares 10-K · filed 2016-02-26 | |
| 2012-12-31 | 420.31K shares 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |